Literature DB >> 31932873

Is cinnarizine/betahistine combination superior to respective monotherapies in treatment of vertigo? Comment on a randomized triple-blind placebo-controlled trial.

Kiumarth Amini1, Maryam Taghizadeh-Ghehi2.   

Abstract

Entities:  

Year:  2020        PMID： 31932873     DOI： 10.1007/s00228-020-02833-z

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  5 in total

1.  Cinnarizine/betahistine combination vs. the respective monotherapies in acute peripheral vertigo: a randomized triple-blind placebo-controlled trial.

Authors:  Payman Asadi; Seyyed Mahdi Zia Ziabari; Alireza Majdi; Karim Vatanparast; Seyed Ahmad Naseri Alavi
Journal:  Eur J Clin Pharmacol       Date:  2019-08-16       Impact factor: 2.953

2.  Efficacy of acetylleucine in vertigo and dizziness: a systematic review of randomised controlled trials.

Authors:  Paul Vanderkam; Clara Blanchard; Florian Naudet; Denis Pouchain; Helene Vaillant Roussel; Marie Christine Perault-Pochat; Nematollah Jaafari; Rémy Boussageon
Journal:  Eur J Clin Pharmacol       Date:  2019-01-06       Impact factor: 2.953

3.  Efficacy and Tolerability of a Fixed Combination of Cinnarizine and Dimenhydrinate versus Betahistine in the Treatment of Otogenic Vertigo : A Double-Blind, Randomised Clinical Study.

Authors:  Zdenek Cirek; Mario Schwarz; Wolfgang Baumann; Miroslav Novotny
Journal:  Clin Drug Investig       Date:  2005       Impact factor: 2.859

Review 4.  Betahistine for symptoms of vertigo.

Authors:  Louisa Murdin; Kiran Hussain; Anne G M Schilder
Journal:  Cochrane Database Syst Rev       Date:  2016-06-21

5.  Efficacy and Safety of a Fixed Combination of Cinnarizine 20 mg and Dimenhydrinate 40 mg vs Betahistine Dihydrochloride 16 mg in Patients with Peripheral Vestibular Vertigo: A Prospective, Multinational, Multicenter, Double-Blind, Randomized, Non-inferiority Clinical Trial.

Authors:  Arne W Scholtz; Ales Hahn; Bohdana Stefflova; Daniela Medzhidieva; Sergey V Ryazantsev; Alexander Paschinin; Natalia Kunelskaya; Kai Schumacher; Gerhard Weisshaar
Journal:  Clin Drug Investig       Date:  2019-11       Impact factor: 2.859
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.